Monday, 22 Jan 2018

You are here

Cochrane Review: Calcium Channel Blocker Efficacy in Raynaud's

The Cochrane Database has published its review of calcium channel blockers (CCB) in Raynaud's phenomenon, showing CCBs may be useful in reducing the frequency, duration, severity of attacks, pain and disability associated with Raynaud's phenomenon, especially with primary Raynaud's.

In their review they distinguished primary Raynaud's phenomenon (not associated with underlying disease) from secondary Raynaud's phenomenon (associated with connective tissue disorders).

They analyzed data from 1946 to 2017, specifically looking for randomized controlled trials (RCTs) comparing calcium channel blockers versus placebo.

They identified 38 RCTs (33 cross-over RCTs) with an average duration of 7.4 weeks and 982 participants.

Nine of the identified trials studied patients with primary Raynaud's phenomenon (N = 365), five studied patients with secondary Raynaud's phenomenon (N = 63), and the rest examined a mixture of patients with primary and secondary Raynaud's phenomenon (N = 554).

Looking at both primary and secondary Raynaud's phenomenon, evidence (moderate quality) from 23 trials with 528 participants shows CCBs were superior to placebo in reducing the frequency of attacks, severity of attacks, and Raynaud's pain (low-quality evidence).

The most common side effects were headache, dizziness, nausea, palpitations, and ankle edema. However, in all trials, no serious adverse events (death or hospitalization) were reported.

Randomized controlled trials with evidence of low to moderate quality showed that CCBs (especially the dihydropyridine class) may be useful in reducing the frequency, duration, severity of attacks, pain and disability associated with Raynaud's phenomenon. Higher doses may be more effective than lower doses and these CCBs may be more effective in primary RP. Although there were more withdrawals due to adverse events in the treatment groups, no serious adverse events were reported.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Stroke Risk Confirmed in SLE

The most common cerebrovascular events (CVEs) seen among a large cohort of patients with systemic lupus erythematosus (SLE) were stroke and transient ischemia, and the majority of these events were attributable to the disease itself, a multinational study determined.

Stem Cell Transplant Succeeds in Scleroderma

Myeloablative autologous stem cell transplantation was significantly more effective than 12 months of cyclophosphamide among patients with severe scleroderma, an open-label multicenter study found.

Stroke Risk Highest in the First Year of Lupus (Best of 2017)

Arkema et al has published in Annals of Rheumatic Disease a study showing that ischaemic and haemorrhagic stroke (CVA) is elevated in systemic lupus erythematosus (SLE) compared with the general population, especially in the first year. 

Death Rates from Lupus Remain Disproportionately High (Best of 2017)

The Annals of Internal Medicine reports that despite improving trends in mortality, death rates from systematic lupus erythematosus (lupus) remain high compared to those in the general population, and disparities persist between subpopulations and geographic regions. Underreporting of lupus on death certificates may have resulted in underestimates of mortality rates. 

Registry Efficacy of Rituximab in Refractory SLE

Despite large randomized trials failing to show the efficacy of RTX in SLE (LUNAR, EXPLORER), uncontrolled observational data suggests possible efficacy and safety of RTX in refractory SLE.